112 related articles for article (PubMed ID: 22323315)
1. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
Schott S; Niessner H; Sinnberg T; Venturelli S; Berger A; Ikenberg K; Villanueva J; Meier F; Garbe C; Busch C
Int J Cancer; 2012 Nov; 131(9):2165-74. PubMed ID: 22323315
[TBL] [Abstract][Full Text] [Related]
2. ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.
Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
Invest New Drugs; 2011 Jun; 29(3):506-13. PubMed ID: 19997962
[TBL] [Abstract][Full Text] [Related]
3. Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines.
Eicher C; Dewerth A; Ellerkamp V; Fuchs J; Schott S; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):121-7. PubMed ID: 23187893
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Schott H; Schott S; Schwendener RA
Bioorg Med Chem; 2009 Oct; 17(19):6824-31. PubMed ID: 19744858
[TBL] [Abstract][Full Text] [Related]
5. Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.
Weinreich J; Schott S; Königsrainer I; Zieker D; Königsrainer A; Schott H
Invest New Drugs; 2011 Dec; 29(6):1294-302. PubMed ID: 20596746
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity and antileukaemic activity of new duplexes linking 3-C-ethynylcytidine and 5-fluorodeoxyuridine.
Novotny L; Rauko P; Schott H
Anticancer Res; 2010 Dec; 30(12):4891-8. PubMed ID: 21187467
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis in cervical cancer cells by the duplex drug 5-FdU-ECyd, coupling 2'-deoxy-5-fluorouridine and 3'-C-ethinylcytidine.
Schott S; Brüning A
Gynecol Oncol; 2014 Nov; 135(2):342-8. PubMed ID: 25178996
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of gastric adenocarcinoma and normal cell lines against combined or conjugated antimetabolites.
Weinreich J; Struller F; Küper M; Hack A; Königsrainer A; Schott TC
Anticancer Drugs; 2013 Apr; 24(4):375-83. PubMed ID: 23358120
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
Schott S; Vallet S; Tower RJ; Noor S; Tiwari S; Schem C; Busch C
Invest New Drugs; 2015 Aug; 33(4):816-26. PubMed ID: 25986684
[TBL] [Abstract][Full Text] [Related]
10. The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells
Schott S; Wimberger P; Klink B; Grützmann K; Puppe J; Wauer US; Klotz DM; Schröck E; Kuhlmann JD
Oncotarget; 2017 Sep; 8(44):76935-76948. PubMed ID: 29100359
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
Ludwig PS; Schwendener RA; Schott H
Eur J Med Chem; 2005 May; 40(5):494-504. PubMed ID: 15893023
[TBL] [Abstract][Full Text] [Related]
12. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
13. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Cattaneo-Pangrazzi RM; Schott H; Schwendener RA
Prostate; 2000 Sep; 45(1):8-18. PubMed ID: 10960838
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).
Hrdlicka PJ; Jepsen JS; Nielsen C; Wengel J
Bioorg Med Chem; 2005 Feb; 13(4):1249-60. PubMed ID: 15670934
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro.
Weinreich J; Struller F; Sautkin I; Giuashvili S; Reymond M; Königsrainer A; Schott TC
Invest New Drugs; 2019 Jun; 37(3):415-423. PubMed ID: 30019100
[TBL] [Abstract][Full Text] [Related]
16. [Antisense oligonucleotides with antitumor activity].
Otvös L; Sági G
Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
[TBL] [Abstract][Full Text] [Related]
17. 3'-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction.
Fukushima H; Abe T; Sakamoto K; Tsujimoto H; Mizuarai S; Oie S
BMC Cancer; 2014 Aug; 14():562. PubMed ID: 25087851
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.
Bijnsdorp IV; Schwendener RA; Schott H; Fichtner I; Smid K; Laan AC; Schott S; Losekoot N; Honeywell RJ; Peters GJ
Invest New Drugs; 2011 Apr; 29(2):248-57. PubMed ID: 19957099
[TBL] [Abstract][Full Text] [Related]
19. PK-PD modeling of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and the enhanced antitumor effect of its phospholipid derivatives in long-circulating liposomes.
Takada A; Kamiya H; Shuto S; Matsuda A; Harashima H
Int J Pharm; 2009 Jul; 377(1-2):52-9. PubMed ID: 19426792
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor effect and mechanism of a novel multifunctional nucleoside, 3'-ethynylnucleoside, on human cancers].
Tanaka M; Tabata S; Matsuda A; Fukushima M; Eshima K; Sasaki T
Gan To Kagaku Ryoho; 1997 Feb; 24(4):476-82. PubMed ID: 9063487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
